共 50 条
- [1] Tofacitinib, an oral, small-molecule Janus kinase inhibitor, in the treatment of ulcerative colitis: Analysis of an open-label, long-term extension study with up to 5.9 years of treatment[J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S100 - S101Lichtenstein, G. R.Loftus, E. V., Jr.Wei, S. C.Damiao, A. O.Judd, D.Lawendy, N.Chan, G.Zhang, H.Wang, W.Thorpe, A. J.Bloom, S.
- [2] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: Open-Label, Long-term Extension Study[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S395 - S395Lichtenstein, Gary R.Loftus, Edward V., Jr.Bloom, StuartLawendy, NervinFriedman, Gary S.Zhang, HaiyingWang, WenjinThorpe, Andrew J.Nduaka, Chudy I.Su, Chinyu
- [3] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: An Interim Analysis of an Open-Label, Long-Term Extension Study With up to 4.9 Years of Treatment[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S328 - S328Lichtenstein, Gary R.Loftus, Edward V., Jr.Bloom, StuartLawendy, NervinChan, GaryFriedman, Gary S.Zhang, HaiyingWang, WenjinThorpe, Andrew J.Nduaka, Chudy I.Su, Chinyu
- [4] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: An Interim Analysis of an Open-Label, Long-Term Extension Study With up to 5.5 Years of Treatment[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S413 - S414Lichtenstein, Gary R.Loftus, Edward V., Jr.Soonasra, ArifLawendy, NervinChan, GaryZhang, HaiyingWang, WenjinThorpe, Andrew J.Bloom, Stuart
- [5] TOFACITINIB, AN ORAL JAK INHIBITOR, IN THE TREATMENT OF ULCERATIVE COLITIS: OPEN-LABEL, LONG-TERM EXTENSION STUDY[J]. GUT, 2018, 67 : A62 - A63Bloom, StuartLichtenstein, Gary R.Loftus, Edward V.Lawendy, NervinFriedman, Gary S.Zhang, HaiyingWang, WenjinThorpe, Andrew J.Nduaka, Chudy I.Su, Chinyu
- [6] Tofacitinib, An Oral Janus Kinase Inhibitor, In The Treatment Of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy Up To 5 Years[J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S993 - S993Wollenhaupt, JuergenSilverfield, JoelLee, Eun BongWood, Susan P.Terry, Ketti K.Nakamura, HiroyukiOhno, YukakoGruben, DavidBenda, BirgittaWang, LisyRiese, Richard
- [7] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, FOR THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN OPEN-LABEL, LONG-TERM EXTENSION UP TO 6 YEARS[J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 259 - 259Wollenhaupt, J.Silverfield, J.Lee, E. B.Wood, S. P.Terry, K. K.Nakamura, H.Kwok, K.Anisfeld, A.Nduaka, C.Wang, L.
- [8] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension up to 6 Years.[J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S375 - S375Wollenhaupt, J.Silverfield, J.Lee, E. B.Wood, S. P.Terry, K.Nakamura, H.Kwok, K.Anisfeld, A.Nduaka, C.Riese, R.Wang, L.
- [9] Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (04) : 464 - 478Sandborn, William J.Lawendy, NervinDanese, SilvioSu, ChinyuLoftus, Edward V., Jr.Hart, AilsaDotan, IrisDamiao, Aderson O. M. C.Judd, Donna T.Guo, XiangModesto, IreneWang, WenjinPanes, Julian
- [10] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy up to 48 Months[J]. ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S548 - S549Wollenhaupt, JurgenSilverfield, Joel C.Lee, Eun BongWood, Susan P.Soma, KoshikaWang, LisyNakamura, HiroyukiKomuro, YoshihiroNduaka, Chudi I.Gruben, DavidBenda, BirgittaZwillich, Samuel H.Riese, RichardBradley, John D.